Your browser doesn't support javascript.
loading
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman, Ahmed A; Chatamra, Krai; Mohamed, Mohamed-Eslam F; Dutta, Sandeep; Benesh, Janet; Yanagawa, Masayoshi; Nagai, Masahiro.
Afiliação
  • Othman AA; Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Building AP13A-3, North Chicago, IL, 60064, USA, ahmed.othman@abbvie.com.
Clin Pharmacokinet ; 54(9): 975-84, 2015 Sep.
Article em En | MEDLINE | ID: mdl-25875940
ABSTRACT
BACKGROUND AND

OBJECTIVE:

Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson's disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa-carbidopa intestinal gel (LCIG) provides individualized continuous levodopa-carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD.

METHODS:

Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (101 levodopacarbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (41 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed.

RESULTS:

Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased "Off" time (2.68 h, P = 0.002) and increased "On" time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary(©). With the small sample size, no statistically significant changes were seen on other efficacy endpoints.

CONCLUSIONS:

In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Carbidopa / Levodopa Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Carbidopa / Levodopa Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article